A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
Price : $35 *
At a glance
- Drugs Oxcarbazepine (Primary) ; Morphine
- Indications Cancer pain
- Focus Adverse reactions
- 25 Aug 2016 Status changed from recruiting to discontinued due to poor accrual.
- 11 Dec 2014 Planned End Date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 21 Mar 2014 New trial record